MX2019015348A - Anticuerpos contra receptor 1 huerfano tipo receptor de tirosina cinasa (ror1). - Google Patents

Anticuerpos contra receptor 1 huerfano tipo receptor de tirosina cinasa (ror1).

Info

Publication number
MX2019015348A
MX2019015348A MX2019015348A MX2019015348A MX2019015348A MX 2019015348 A MX2019015348 A MX 2019015348A MX 2019015348 A MX2019015348 A MX 2019015348A MX 2019015348 A MX2019015348 A MX 2019015348A MX 2019015348 A MX2019015348 A MX 2019015348A
Authority
MX
Mexico
Prior art keywords
antibodies
ror1 antibodies
ror1
cancer
prevention
Prior art date
Application number
MX2019015348A
Other languages
English (en)
Inventor
Amit Nathwani
Satyen Gohil
Peruta Marco Della
Original Assignee
Ucl Business Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucl Business Ltd filed Critical Ucl Business Ltd
Publication of MX2019015348A publication Critical patent/MX2019015348A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describen anticuerpos contra receptor 1 huérfano tipo receptor de tirosina cinasa (ROR1) que unen específicamente un polipéptido ROR1 y su uso. En particular, los anticuerpos monoclonales aislados se describen y su uso en numerosas aplicaciones que incluyen la detección, prevención y tratamiento de cáncer.
MX2019015348A 2017-07-05 2018-07-05 Anticuerpos contra receptor 1 huerfano tipo receptor de tirosina cinasa (ror1). MX2019015348A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1710835.8A GB201710835D0 (en) 2017-07-05 2017-07-05 ROR1 Antibodies
PCT/GB2018/051914 WO2019008377A1 (en) 2017-07-05 2018-07-05 ANTIBODY ROR1

Publications (1)

Publication Number Publication Date
MX2019015348A true MX2019015348A (es) 2020-07-20

Family

ID=59592560

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019015348A MX2019015348A (es) 2017-07-05 2018-07-05 Anticuerpos contra receptor 1 huerfano tipo receptor de tirosina cinasa (ror1).

Country Status (9)

Country Link
US (2) US11466083B2 (es)
EP (1) EP3649152A1 (es)
JP (1) JP7242573B2 (es)
CN (1) CN110891973B (es)
AU (1) AU2018297630A1 (es)
CA (1) CA3068196A1 (es)
GB (1) GB201710835D0 (es)
MX (1) MX2019015348A (es)
WO (1) WO2019008377A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201710835D0 (en) * 2017-07-05 2017-08-16 Ucl Business Plc ROR1 Antibodies
GB201710836D0 (en) * 2017-07-05 2017-08-16 Ucl Business Plc ROR1 Car T-Cells
WO2020018964A1 (en) 2018-07-20 2020-01-23 Fred Hutchinson Cancer Research Center Compositions and methods for controlled expression of antigen-specific receptors
WO2022040506A2 (en) * 2020-08-21 2022-02-24 Yale University Nanobody compositions and methods of use of the same
JP2023538945A (ja) * 2020-08-24 2023-09-12 エピムアブ、バイオセラピューティクス、（ホンコン）、リミテッド 抗ｒｏｒ１抗体及び関連の二重特異性結合タンパク質
EP4209509A1 (en) * 2020-09-03 2023-07-12 Harbour Biomed (Shanghai) Co., Ltd Ror1-targeting antibody or antigen-binding fragment thereof, preparation method therefor, and application thereof
US20230416356A1 (en) * 2020-11-23 2023-12-28 Scout Bio, Inc. Antigen-binding molecules and uses thereof
WO2022182562A1 (en) * 2021-02-23 2022-09-01 BioLegend, Inc. ANTI-SARS-CoV-2 SPIKE GLYCOPROTEIN S1 AGENTS AND COMPOSITIONS
CN115151572B (zh) * 2021-07-23 2023-09-15 浙江时迈药业有限公司 针对ror1的抗体及其用途
CN113956359B (zh) * 2021-10-29 2022-09-16 叶鑫淼 一种抗体及其在抗肿瘤中的应用
CN118302448A (zh) * 2021-12-28 2024-07-05 江苏恒瑞医药股份有限公司 抗ror1抗体和抗ror1抗体药物偶联物及其医药用途
TW202413422A (zh) * 2022-07-11 2024-04-01 美商翰森生物有限責任公司 抗體、其抗原結合片段及其藥物用途
CN115724973B (zh) * 2022-09-26 2023-07-11 普健生物（武汉）科技有限公司 抗人ror1高亲和力兔单克隆抗体及其应用
CN116903740B (zh) * 2023-04-21 2024-04-30 星奕昂(上海)生物科技有限公司 靶向ror1的抗体及其应用

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101229731B1 (ko) 2003-10-16 2013-03-07 암젠 리서치 (뮌헨) 게엠베하 다중특이적 탈면역화된 ｃｄ3-바인더
WO2007146957A2 (en) 2006-06-13 2007-12-21 Irm Llc Ror1 as a therapeutic target for lung cancer
EP2421899B1 (en) 2009-04-23 2016-06-08 The United States of America, as represented by The Secretary, Department of Health and Human Services Anti-human ror1 antibodies
WO2011054007A1 (en) * 2009-11-02 2011-05-05 Oxford Biotherapeutics Ltd. Ror1 as therapeutic and diagnostic target
ES2635316T3 (es) 2009-12-18 2017-10-03 Kancera Ab Anticuerpos contra ROR1 que pueden inducir muerte celular de LLC
EP3219731A1 (en) 2010-10-01 2017-09-20 Oxford BioTherapeutics Ltd Anti-ror1 antibodies
CA2818992C (en) 2010-12-01 2021-05-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric rabbit/human ror1 antibodies
GB201020995D0 (en) 2010-12-10 2011-01-26 Bioinvent Int Ab Biological materials and uses thereof
ES2634098T3 (es) 2011-01-14 2017-09-26 The Regents Of The University Of California Anticuerpos terapéuticos contra la proteína ROR-1 y procedimientos para el uso de los mismos.
SG11201501259QA (en) 2012-08-20 2015-03-30 Hutchinson Fred Cancer Res Method and compositions for cellular immunotherapy
US9758591B2 (en) * 2012-08-24 2017-09-12 The Regents Of The University Of California Antibodies and vaccines for use in treating ROR1 cancers and inhibiting metastasis
EP2789630A1 (en) 2013-04-09 2014-10-15 EngMab AG Bispecific antibodies against CD3e and ROR1
RU2718692C2 (ru) 2014-05-29 2020-04-13 Мэкроудженикс, Инк. Триспецифичные связывающие молекулы, которые специфически связывают антигены множества злокачественных опухолей, и способы их применения
DK3453406T3 (da) 2014-07-29 2021-07-12 Cellectis ROR1(NTRKR1)-specifikke kimære antigenreceptorer til cancerimmunterapi
JP2017522893A (ja) 2014-07-31 2017-08-17 セレクティスＣｅｌｌｅｃｔｉｓ Ｒｏｒ１特異的多重鎖キメラ抗原受容体
RU2753512C2 (ru) 2014-09-08 2021-08-17 Нэшнл Кэнсер Сентер Антитело против злокачественной клетки, противораковое лекарственное средство и способ тестирования злокачественного новообразования
CA2963692A1 (en) 2014-10-09 2016-04-14 Engmab Ag Bispecific antibodies against cd3epsilon and ror1
US20170306044A1 (en) 2014-10-09 2017-10-26 Engmab Ag Bispecific antibodies against cd3epsilon and ror1 for use in the treatment of ovarian cancer
WO2016094873A2 (en) 2014-12-12 2016-06-16 Emergent Product Development Seattle, Llc Receptor tyrosine kinase-like orphan receptor 1 binding proteins and related compositions and methods
EP3245231B1 (en) * 2015-01-16 2020-08-12 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for ror1
KR102493943B1 (ko) 2015-02-02 2023-01-31 칸세라 아베 포유류 티로신 키나제 ROR1 활성의 저해제로서 유용한 2-페닐-3H-이미다조[4,5-b]피리딘 유도체
EP3298032A1 (en) 2015-05-18 2018-03-28 Bluebird Bio, Inc. Anti-ror1 chimeric antigen receptors
US11155615B2 (en) 2015-05-18 2021-10-26 Eureka Therapeutics, Inc. Anti-ROR1 antibodies
WO2017072361A1 (en) 2015-10-30 2017-05-04 Nbe-Therapeutics Ag Anti-ror1 antibodies
CA3011815A1 (en) 2016-01-20 2017-07-27 The Scripps Research Institute Ror1 antibody compositions and related methods
MX2018008934A (es) 2016-01-22 2019-03-28 Janssen Biotech Inc Anticuerpos anti-ror1, anticuerpos biespecíficos ror1 x cd3 y métodos para su uso.
UY37127A (es) 2016-02-17 2017-08-31 Macrogenics Inc Moléculas de unión a ror1, y métodos de uso de las mismas
WO2017156479A1 (en) 2016-03-11 2017-09-14 Bluebird Bio, Inc. Ror1 chimeric antigen receptors
KR102466810B1 (ko) 2016-07-11 2022-11-11 칸세라 아베 포유류 티로신 키나제 ror1 활성의 저해제로서 유용한 2-페닐이미다조[4,5-b]피리딘-7-아민 유도체
US20200338210A1 (en) 2016-12-22 2020-10-29 Ardeagen Corporation Anti-ror1 antibody and conjugates thereof
BR112019024654A2 (pt) 2017-05-23 2020-06-09 Dragonfly Therapeutics Inc proteína de ligação nkg2d, cd16 e ror1 ou ror2
EP3641830A1 (en) 2017-06-23 2020-04-29 Velosbio Inc. Ror1 antibody immunoconjugates
JP7323513B2 (ja) 2017-06-25 2023-08-08 システィミューン， インク． 抗４－１ｂｂ抗体とその作製及び使用方法
GB201710836D0 (en) * 2017-07-05 2017-08-16 Ucl Business Plc ROR1 Car T-Cells
GB201710838D0 (en) * 2017-07-05 2017-08-16 Ucl Business Plc Bispecific antibodies
GB201710835D0 (en) * 2017-07-05 2017-08-16 Ucl Business Plc ROR1 Antibodies
EP3655435A1 (en) 2017-07-20 2020-05-27 NBE-Therapeutics AG Multispecific antibody product that binds to different ror1 epitopes
KR20230008269A (ko) 2017-08-07 2023-01-13 엔비이-테라퓨틱스 아게 생체 내 내성이 높은 항체 약물 결합체
CN111741757B (zh) 2017-11-03 2023-12-19 莱蒂恩技术公司 用于用抗ror1免疫治疗来治疗癌症的组合物和方法
GB201721802D0 (en) 2017-12-22 2018-02-07 Almac Discovery Ltd Ror1-specific antigen binding molecules
WO2019225777A1 (ko) 2018-05-23 2019-11-28 에이비엘바이오 주식회사 항-ror1 항체 및 그 용도

Also Published As

Publication number Publication date
US20230220073A1 (en) 2023-07-13
CA3068196A1 (en) 2019-01-10
EP3649152A1 (en) 2020-05-13
JP2020530272A (ja) 2020-10-22
GB201710835D0 (en) 2017-08-16
WO2019008377A1 (en) 2019-01-10
AU2018297630A1 (en) 2020-01-16
CN110891973B (zh) 2023-06-27
US20200354448A1 (en) 2020-11-12
US11466083B2 (en) 2022-10-11
CN110891973A (zh) 2020-03-17
JP7242573B2 (ja) 2023-03-20

Similar Documents

Publication Publication Date Title
MX2019015348A (es) Anticuerpos contra receptor 1 huerfano tipo receptor de tirosina cinasa (ror1).
CY1125260T1 (el) Παραγοντες δεσμευσης tigit και χρησεις τους
PH12021550152A1 (en) Anti-cd112r compositions and methods
SA518400222B1 (ar) أجسام مضادة لـ وتركيبات tim-3
MX2020009649A (es) Anticuerpos monoclonales contra bcma.
PH12018500815A1 (en) Antibody conjugates comprising toll-like receptor agonist
MX2017004311A (es) Anticuerpos del receptor del factor de necrosis tumoral inducido por glucocorticoide (gitr) y metodos de uso de los mismos.
MX2022004072A (es) Anticuerpos de factor xi y metodos de uso.
NZ753515A (en) Methods for treatment of cancer comprising tigit-binding agents
MX2021013586A (es) Anticuerpo monoclonal anti-antigeno 4 asociado a linfocitos t citotoxicos (ctla4) o su fragmento de union a antigeno, una composicion farmaceutica y uso.
WO2017031458A3 (en) Anti-dll3 antibody drug conjugates and methods of use
MX2019015352A (es) Linfocitos t con receptor de antigeno quimerico (car) para receptor 1 huerfano tipo receptor de tirosina cinasa (ror 1).
MX2020007748A (es) Metodos para tratar canceres con anticuerpos anti-pd-1 antagonistas.
CL2018003608A1 (es) Anticuerpo aislado o fragmento de unión a antígeno del mismo que se une específicamente interleucina-25 hjumana (il-2525); composición farmacéutica que lo comprende; uso de dicha composición farmacéutica para tratar una enfermedad o trastorno asociado con la actividad o expresión de il-25. (divisional solicitud 201700703)
IL291545A (en) Antibodies against ctla4, antibody fragments, their immunoconjugates and their uses
MX2020005364A (es) Anticuerpos anti-ox40 y usos de los mismos.
PH12019501605A1 (en) Glucagon receptor binding proteins and methods of use thereof
EA201891527A1 (ru) Композиции и способы обнаружения и лечения рака пищевода
EA201891528A1 (ru) Композиции и способы обнаружения и лечения рака желудка
MX2024003627A (es) Anticuerpos contra el receptor del factor de necrosis tumoral inducido por glucocorticoides (gitr) y sus metodos de uso.
SG11202108832XA (en) Anti-ang2 antibody and use thereof
MX2018004228A (es) Anticuerpo que se une especificamente a erbb3 y uso de este.
WO2016135462A8 (en) Treatment
EA202092573A1 (ru) Композиции и способы обнаружения и лечения рака желудка
PL416359A1 (pl) Przeciwciała monoklonalne rozpoznające swoiście psi antygen DLA-DR i ich zastosowania